Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03688178
Title DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gary Archer Ph.D.
Indications

glioblastoma

Therapies

pp65 Dendritic Cell Vaccine + Temozolomide

pp65 Dendritic Cell Vaccine + Temozolomide + Varlilumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.